2012 revenue: $27.4 billion
2011 revenue: $25.7 billion
Year in review: For Johnson & Johnson ($JNJ), its $21.3 billion buyout of orthopedics giant Synthes in 2012 paid off with a 6.4% spike in device revenue growth and a 34.3% explosion in orthopedics sales. But it came none too soon, considering the company's other device businesses languished. Cardiovascular revenue, for example, dropped 13.2% and diagnostics dropped 4.4%. Of course, the numbers could have been better, save for recalls and lawsuits. J&J's recall of its ASR metal-on-metal hip implants has led to thousands of lawsuits. For the 2012 fourth quarter alone, the consumer products giant took $800 million in charges to cover litigation and related costs. But 2012 also represented a revenue milestone of a different sort: Devices and diagnostics are now J&J's largest business units by far.
J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy